Clovis Oncology (CLVS) Peer Comparison

$0.09

$0.00 (3.33%)

As on 22-Feb-2023 09:30EDT

Market cap

$12 Mln

Revenue (TTM)

$133 Mln

P/E Ratio

--

P/B Ratio

0

Div. Yield

0 %

Edit

	Clovis Oncology (CLVS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Market cap ($ Mln)	12	17,326	13,400	12,305	12,277
Revenue ($ Mln)	133	2,782	2,436	670	1,664
Net Profit ($ Mln)	-251.91	491.50	860.62	-319.95	413.60
Net Margin (%)	-202.26	17.67	35.33	-47.79	24.86
RoE (%)	--	110.09	42.98	-71.14	430.03
Price to Earnings	--	36.49	17.01	--	31.17
Price-To-Book	--	39.43	7.27	26.44	83.92

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Clovis Oncology (CLVS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Operating Revenue	133.02	1,142.38	1,434.97	138.29	443.31
Cost of Revenue	35.62	814.22	52.87	--	81.41
Gross Profit	109.93	328.16	1,382.10	138.29	361.90
Operating Expenses	297.62	129.54	1,095.43	287.32	86.00
Operating Profit (EBIT)	-230.88	198.62	286.67	-149.04	275.90
Other Income	-8.48	3.34	-0.18	2.07	-19.86
Profit before Tax	-252.31	201.85	294.15	-140.85	248.52
Provision for Tax	-0.41	20.00	63.09	0.00	-154.19
Profit after Tax (Net Income)	-251.91	181.85	231.06	-140.85	402.71
Minority Interest	0.00	--	--	--	--
Consolidated Profit	-251.90	181.85	231.06	-140.85	402.71

Liabilities ($ Mln)

	Clovis Oncology (CLVS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Shareholder's Funds	-417.89	952.93	2,210.62	408.82	196.95
Minority Interest	0.00	--	--	--	--
Non-Current Liabilities	455.11	149.79	68.03	154.79	790.33
Current Liabilities	747.87	557.22	337.59	146.54	117.15
Total Liabilities	472.83	1,659.94	2,616.24	710.15	1,104.43

Assets ($ Mln)

	Clovis Oncology (CLVS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Non-Current Assets	244.57	969.02	781.49	325.55	178.14
Current Assets	102.21	690.91	1,834.75	384.60	926.29
Total Assets	472.83	1,659.94	2,616.24	710.15	1,104.43
Total Debt*	458.57	130.97	51.27	25.55	876.67
Net Current Assets	-645.66	133.70	1,497.16	238.06	809.14

Cashflow ($ Mln)

	Clovis Oncology (CLVS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Cash From Operating Activities	-196.06	263.33	400.80	171.31	299.44
Cash Flow from Investing Activities	-0.31	-31.36	-42.88	-141.68	-406.29
Cash from Financing Activities	100.16	-44.45	-14.80	11.31	77.87
Net Cash Inflow / Outflow	-96.21	187.51	52.64	40.85	-28.98

Ratios

Profitability Ratios

	Clovis Oncology (CLVS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
ROCE (%)	-62.41	18.14	11.03	-30.71	49.66
ROE (%)	120.90	20.68	11.30	-32.36	231.44
ROA (%)	-29.37	11.92	9.72	-22.85	47.82
EBIT Margin (%)	-163.01	--	--	--	--
Net Margin (%)	-202.26	15.87	16.10	-100.35	95.10
Cash Profit Margin (%)	0.00	--	--	--	--

Growth Ratios

	Clovis Oncology (CLVS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Revenue Growth (%)	-14.78	0.23	0.45	0.57	0.66
EBIT Growth (%)	19.45	--	--	--	--
Net Profit Growth (%)	15.78	25.08	106.71	-66.58	211.97
EPS Growth (%)	--	0.25	1.04	-0.64	2.14
Book Value Growth (%)	--	--	--	--	--

Valuation Ratios

	Clovis Oncology (CLVS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Price / Earnings	--	45.17	25.57	-46.33	14.40
Price / Book Value	--	8.62	2.67	15.96	29.45
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-2.20	35.34	14.96	-46.64	21.28
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Clovis Oncology (CLVS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Debt to Equity	0.00	0.14	0.02	0.06	4.45
Short term debt to equity ratio	-0.01	0.17	0.00	0.01	0.45
Current Ratio	0.14	1.24	5.43	2.62	7.91
Quick Ratio	0.12	--	5.35	2.59	7.45
Interest Coverage	-6.11	1,923.40	--	-23.01	36.66

Operating Efficiency Ratios

	Clovis Oncology (CLVS)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Debtors to sales (%)	14.62	16.32	19.70	7.42	20.52
Asset Turnover	0.16	0.75	0.60	0.22	0.53
Receivable days	78.90	55.54	56.45	14.66	77.74
Inventory Days	208.85	0.00	167.40	--	257.19
Payable days	254.00	11.71	165.41	--	7.78
Cash Conversion Cycle	33.76	48.64	58.44	--	327.15

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly